20+ Years Expertise In ICH Or FDA Bioanalytical Method Validation Services GLP Or Fit-For-Purpose!

The developed assay must be specific for the analyte(s) and internal standard in the blank matrix. At least six independent matrix blanks must be analyzed to show that no interferences are arising from different lots of plasma. Assay qualification ensures that the method is capable of consistently identifying and quantifying the analyte(s) in different sample matrices.

The degree to which the signal is suppressed by the extracted components of the matrix is assessed by injecting solutions of the analyte prepared in reconstituted blank matrix extracts and comparing the signal to the analyte prepared in the mobile phase or reconstitution solution. Values are reported as percent suppression. In some instances, signal enhancement is observed.

The ability of the assay to accurately and reproducibly quantitate the analyte(s) in different lots of the matrix is assessed by spiking six independent lots to a concentration equivalent to the QC_Low concentration. Assay qualification is performed to ensure the method is fit for its intended purpose before full validation.

• Calibration standards should be prepared in the matrix same as the study samples.
• Calibration curve should consist of a minimum of six concentration levels analyzed in singlet or duplicate.
• One matrix blank (Control) and one zero sample (i.e., matrix blank with IS, Control IS) should be included in each validation run.

• The back-calculated concentrations of the individual standards must be within accepted deviation from the nominal value.
• Deletion of calibrators should be done one at a time in a sequential manner beginning with the most deviant calibrator.
• At least 3/4^th of the original calibration standards are mandatory to meet the accuracy requirements.
• The quantitation range of the study samples should not be affected by these changes. At least one standard calibrator at the LLOQ and ULQ must be within specification.
• If the quantitation range is modified, three quality control levels within the adjusted calibration range should fulfill the accuracy requirements.

The inter-day accuracy and precision should be calculated using the data from three one-day validation runs. Precision is based on the percent coefficient of variation (%CV) observed by the mean of the QC samples at each QC concentration level.

• Accuracy and precision should be calculated using the mean concentration results of the QC samples at each level. Precision should be based on the percent coefficient of variation (%CV) observed by the mean at each quality control concentration level.
• Dixon test for the outliers: Dixon test is applied to the percent accuracy determined for the QCs based on the theoretical and measured concentrations of the QCs from the standard curve.
• Outliers may be omitted from the precision and accuracy calculation after performing the Dixon test.

• During method validation runs, a double-blank sample should be injected after the highest calibration standard to determine if the equipment is cross-contaminating the sample during loading.
• Peak response for the analyte(s) due to carryover must not be more than a specified % of the response of the lowest calibration standard (LLOQ). For internal standard again, the response must not be more than a determined % of the average internal standard response.

• Quality control samples should be prepared at a minimum of four concentration levels (QC_LLOQ, QC_Low, QC_Mid, and QC_High).
• An additional QC level QC_Dil must be included in at least one of the runs to test for dilution integrity.
• Six replicates of each QC concentration levels should be analyzed in each validation run.
• Acceptance criteria for QC: The individual back-calculated concentration of each QC sample for the three in-range QC levels must be within accepted deviations from nominal.

Stability testing should include process stability, as well as short term and long-term stability of analytes in solution and in the matrix.

Ligand Binding Assays (LBAs) are critical analytical techniques used to measure interactions between ligands, such as drugs or hormones, and their specific targets, including receptors or proteins. These assays are pivotal in drug development and therapeutic monitoring, allowing for the assessment of drug concentrations, biological activity, and the efficacy and safety of new therapeutics. The FDA document details various types of LBAs, including immunoassays, radioimmunoassays, enzyme-linked immunosorbent assays, and fluorescence-based assays. It also highlights the importance of validating these assays to ensure accuracy, precision, and regulatory compliance, emphasizing rigorous standards for assay design and performance to support credible results in regulatory submissions.

Batch run size depends on a variety of factors. Consideration during LC-MS analysis includes autosampler stability, run time, column stability, MS stability, etc. Here, the batch size is determined by repeat injection of blanks with QCs at regular intervals during a validation run.

High and low concentrations of QCs should be used to prepare 6 replicates with lipemic plasma (in mg/dL of lipids). Similarly, 6 replicate samples with hemolytic plasma (based on mg/dL of heme) should be analyzed.

The lower limit of quantitation (LLOQ) indicates the lowest concentration of study samples that can be quantitated with acceptable accuracy. The LLOQ is the lowest calibration standard used to generate a calibration curve.

• Recovery of the analyte(s) is calculated using the in-range quality control samples at three different concentration levels. The study compares the responses of the analyte(s) and IS from the validation QCs to the responses in non-extracted samples prepared in mobile phase/reconstitution solvent.
• The percent recovery of the analyte is calculated at each concentration level by dividing the mean response of the analyte (minimum of three determinations) in the matrix sample by the mean response of the analyte at that concentration in the non-extracted samples.
• The percent recovery of the internal standard is calculated by dividing the overall mean response of the internal standard in the matrix samples by the overall mean response of the internal standard in the non-extracted samples.
• Recovery studies for stable-labeled internal standards are not required, since, by definition, it is chemically like the analyte.

• When preparing standards and QCs in a matrix such as plasma, urine, etc., the maximum amount solvent, from a stock standard(s) containing the analyte(s), should not exceed a certain percentage of the total volume.
• This can be calculated using the equation below:

% Stock Standard = spiking amount (ml) / [matrix amount (ml) + spiking amount (ml) *100

• A system suitability sample (SST) must be developed during method validation. In general, the system suitability sample is a combination of all the expected analytes in the assay prepared in a suitable solvent system. This process underscores the concept of assay qualification vs validation, where initial qualification ensures the method’s suitability before moving on to full validation.
• Analyte(s) must be at a concentration that corresponds to the low end of the calibration curve but high enough to give a robust and reproducible signal.
• The strength and the composition of the SST solution must be documented along with a representative chromatogram generated using the SST.
• The representative chromatogram should be used as the baseline for checking if an analytical system is suitable for conducting the validated assay. The parameters to be used for system evaluation are retention time and response. Assay qualification is conducted prior to method validation to ensure the system’s suitability for consistent and accurate analyte quantification. Furthermore, assay qualification vs validation helps to ensure that the method’s performance is assessed thoroughly before full validation.

Whenever possible, the method validation should be done in the matrices for which the assay is intended to be used. If unavailable, then evidence must be provided to demonstrate that a substitute is acceptable.

Reference standards used in the preparation of calibration and Quality Control Samples must have a Certificate of Analysis (CoA) indicating the purity and expiration date. A CoA is not required for the internal standard, but the material must be checked for impurities that may interfere with the analyte(s).